Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
Authors
Keywords
-
Journal
Molecular Cancer
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-03-25
DOI
10.1186/s12943-023-01761-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FIGHT-101, a first-in-human study of potent and selective FGFR 1–3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies
- (2022) V. Subbiah et al. ANNALS OF ONCOLOGY
- Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
- (2022) Michihisa Kono et al. OncoImmunology
- A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
- (2022) Stephen L. Chan et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS , MET , FGFR , RET , BRAF , and HER2 alterations
- (2022) Yuji Uehara et al. Thoracic Cancer
- FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma
- (2022) Min Lu et al. CELLULAR IMMUNOLOGY
- FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures
- (2022) Vishwajith Sridharan et al. CLINICAL CANCER RESEARCH
- FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
- (2022) Zhanchao Tao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Comprehensive analysis of the prognostic value and immune infiltration of FGFR family members in gastric cancer
- (2022) Chengcheng Yang et al. Frontiers in Oncology
- Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma
- (2022) Wengang Zhang et al. Frontiers in Immunology
- Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
- (2021) Guihong Liu et al. CELL PROLIFERATION
- The Role of CXCL16 in the Pathogenesis of Cancer and Other Diseases
- (2021) Jan Korbecki et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Therapeutic Targeting of the Tumor Microenvironment
- (2021) Leire Bejarano et al. Cancer Discovery
- Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
- (2021) Tracy L. Rose et al. BRITISH JOURNAL OF CANCER
- CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment
- (2021) Mauro Di Pilato et al. CELL
- FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response
- (2021) Olga Bogatyrova et al. EUROPEAN JOURNAL OF CANCER
- Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC
- (2021) Chenhe Yi et al. HEPATOLOGY
- Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment
- (2021) Hye Won Lee et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy
- (2021) Hanbing Wang et al. CANCER LETTERS
- Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
- (2021) Yusuke Adachi et al. CANCER RESEARCH
- FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell–Mediated Bladder Cancer Immune Surveillance
- (2021) Weiqiang Jing et al. CANCER RESEARCH
- Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives
- (2021) Xiaoqi Mao et al. Molecular Cancer
- Cancer associated-fibroblast-derived exosomes in cancer progression
- (2021) Chao Li et al. Molecular Cancer
- Response Stratification in the First-Line Combined Immunotherapy of Hepatocellular Carcinoma at Genomic, Transcriptional and Immune Repertoire Levels
- (2021) Jiamin Cheng et al. Journal of Hepatocellular Carcinoma
- Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma
- (2020) Haijing Deng et al. Liver Cancer
- Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
- (2020) Yolla Haibe et al. Frontiers in Oncology
- Hypoxia: Turning vessels into vassals of cancer immunotolerance
- (2020) Luana Schito et al. CANCER LETTERS
- The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
- (2020) Florent Petitprez et al. Frontiers in Immunology
- FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy
- (2020) Jae Hong Im et al. Nature Communications
- 757P An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death-(Ligand) 1 (PD-[L]1) therapy by fibroblast growth factor receptor gene alteration (FGFRa) status
- (2020) A. Rezazadeh et al. ANNALS OF ONCOLOGY
- Pharmacological inhibition of FGFR modulates the metastatic immune microenvironment and promotes response to immune checkpoint blockade
- (2020) Saeed S Akhand et al. Cancer Immunology Research
- Recurrent activating mutations of PPARγ associated with luminal bladder tumors
- (2019) Natacha Rochel et al. Nature Communications
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
- (2019) Yu Kato et al. PLoS One
- Endothelial-to-Mesenchymal Transition
- (2019) Joyce Bischoff CIRCULATION RESEARCH
- Context-dependent EMT programs in cancer metastasis
- (2019) Nicole M. Aiello et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins
- (2019) Latko et al. Cells
- Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer
- (2019) Li Wang et al. EUROPEAN UROLOGY
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling
- (2019) Brian D. Robinson et al. Nature Communications
- The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity
- (2019) Sangeetha Palakurthi et al. Cancer Immunology Research
- First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma
- (2019) Richard D Kim et al. Cancer Discovery
- 933PPrognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting
- (2019) F Roghmann et al. ANNALS OF ONCOLOGY
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- T Cell Dysfunction in Cancer
- (2018) Daniela S. Thommen et al. CANCER CELL
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- TCR Signaling: Mechanisms of Initiation and Propagation
- (2018) Adam H. Courtney et al. TRENDS IN BIOCHEMICAL SCIENCES
- Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
- (2018) Marco B. Schaaf et al. Cell Death & Disease
- Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
- (2018) Christopher Groth et al. BRITISH JOURNAL OF CANCER
- Fibroblast growth factor receptors as treatment targets in clinical oncology
- (2018) Masaru Katoh Nature Reviews Clinical Oncology
- Targeting macrophages: therapeutic approaches in cancer
- (2018) Luca Cassetta et al. NATURE REVIEWS DRUG DISCOVERY
- Crosstalk between receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCR) in the brain: Focus on heteroreceptor complexes and related functional neurotrophic effects
- (2018) Valentina Di Liberto et al. NEUROPHARMACOLOGY
- EMT Transition States during Tumor Progression and Metastasis
- (2018) Ievgenia Pastushenko et al. TRENDS IN CELL BIOLOGY
- T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
- (2017) Robert Sackstein et al. LABORATORY INVESTIGATION
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- FGF-dependent metabolic control of vascular development
- (2017) Pengchun Yu et al. NATURE
- Molecular Biomarkers of Primary and Acquired Resistance to T‐Cell‐Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions
- (2017) Young Kwang Chae et al. ONCOLOGIST
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer
- (2017) Manav Korpal et al. Nature Communications
- Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
- (2017) Apinya Jusakul et al. Cancer Discovery
- Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
- (2017) Takuro Noguchi et al. Cancer Immunology Research
- Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation
- (2017) Marek Wieczorek et al. Frontiers in Immunology
- Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
- (2016) J. M. Pitt et al. ANNALS OF ONCOLOGY
- NCAM- and FGF-2-mediated FGFR1 signaling in the tumor microenvironment of esophageal cancer regulates the survival and migration of tumor-associated macrophages and cancer cells
- (2016) Nobuhisa Takase et al. CANCER LETTERS
- Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
- (2016) Y. Lou et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
- (2016) S. Gettinger et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- The untold story of IFN-γ in cancer biology
- (2016) M. Alper Kursunel et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Counter-regulatory paracrine actions of FGF-23 and 1,25(OH)2D in macrophages
- (2016) Xiaobin Han et al. FEBS LETTERS
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
- (2016) MASARU KATOH INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- FGF23 signaling impairs neutrophil recruitment and host defense during CKD
- (2016) Jan Rossaint et al. JOURNAL OF CLINICAL INVESTIGATION
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer
- (2016) W. S. Brown et al. MOLECULAR CANCER THERAPEUTICS
- Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation
- (2016) Thomas Welte et al. NATURE CELL BIOLOGY
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Regulation of FGF signaling: Recent insights from studying positive and negative modulators
- (2016) Lina Korsensky et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Present Yourself! By MHC Class I and MHC Class II Molecules
- (2016) Kenneth L. Rock et al. TRENDS IN IMMUNOLOGY
- Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
- (2016) Paul E. Hughes et al. TRENDS IN IMMUNOLOGY
- Therapeutics Targeting FGF Signaling Network in Human Diseases
- (2016) Masaru Katoh TRENDS IN PHARMACOLOGICAL SCIENCES
- Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
- (2016) R. F. Sweis et al. Cancer Immunology Research
- Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy
- (2016) Yu Zhang et al. JAMA Oncology
- CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer
- (2015) T. A. Karakasheva et al. CANCER RESEARCH
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially
- (2015) Wenxiu Zhao et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
- (2015) Douglas Marvel et al. JOURNAL OF CLINICAL INVESTIGATION
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction
- (2015) Edward P. Carter et al. TRENDS IN CELL BIOLOGY
- Expression of the FGFR2 mesenchymal splicing variant in epithelial cells drives epithelial-mesenchymal transition
- (2015) Danilo Ranieri et al. Oncotarget
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers
- (2014) Michael K Wendt et al. BREAST CANCER RESEARCH
- Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis
- (2014) Tinghong Ye et al. BREAST CANCER RESEARCH AND TREATMENT
- Reductions in Myeloid-Derived Suppressor Cells and Lung Metastases using AZD4547 Treatment of a Metastatic Murine Breast Tumor Model
- (2014) Li Liu et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- Cell-Surface Receptors Transactivation Mediated by G Protein-Coupled Receptors
- (2014) Fabio Cattaneo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction
- (2014) Christian A. Bauer et al. JOURNAL OF CLINICAL INVESTIGATION
- Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells
- (2014) S. Matsumura et al. JOURNAL OF IMMUNOLOGY
- Acquired and intrinsic resistance in cancer immunotherapy
- (2014) Sander Kelderman et al. Molecular Oncology
- Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis
- (2014) Sunday S. Oladipupo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
- (2014) Limo Chen et al. Nature Communications
- ARF and p53 Coordinate Tumor Suppression of an Oncogenic IFN-β-STAT1-ISG15 Signaling Axis
- (2014) Jason T. Forys et al. Cell Reports
- The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy
- (2014) H.-J. Kim et al. Cancer Immunology Research
- Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
- (2013) Y. Huang et al. CANCER RESEARCH
- Activation of the FGFR-STAT3 Pathway in Breast Cancer Cells Induces a Hyaluronan-Rich Microenvironment That Licenses Tumor Formation
- (2013) L. R. Bohrer et al. CANCER RESEARCH
- Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer
- (2013) S. Cardarella et al. CLINICAL CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- FGF Receptors: Cancer Biology and Therapeutics
- (2013) Masaru Katoh et al. MEDICINAL RESEARCH REVIEWS
- Microenvironmental regulation of tumor progression and metastasis
- (2013) Daniela F Quail et al. NATURE MEDICINE
- N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties
- (2013) X Qian et al. ONCOGENE
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia
- (2012) Yuliya Pylayeva-Gupta et al. CANCER CELL
- High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma
- (2012) Min Ho Park et al. JOURNAL OF SURGICAL ONCOLOGY
- The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer
- (2012) Stephanie Cardarella et al. Journal of Thoracic Oncology
- Fibroblast Growth Factor Receptor 1 Activation in Mammary Tumor Cells Promotes Macrophage Recruitment in a CX3CL1-Dependent Manner
- (2012) Johanna R. Reed et al. PLoS One
- FGF Regulates TGF-β Signaling and Endothelial-to-Mesenchymal Transition via Control of let-7 miRNA Expression
- (2012) Pei-Yu Chen et al. Cell Reports
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
- (2011) B. P. Pollack et al. CLINICAL CANCER RESEARCH
- TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition
- (2011) Takuya Shirakihara et al. EMBO JOURNAL
- Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease
- (2011) N. Itoh et al. JOURNAL OF BIOCHEMISTRY
- Ultra-sensitive detection of rare T cell clones
- (2011) Harlan Robins et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody
- (2011) Greta Garrido et al. JOURNAL OF IMMUNOLOGY
- Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinoma
- (2011) Daniel Schulze et al. Molecular Cancer
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- Macrophages, innate immunity and cancer: balance, tolerance, and diversity
- (2010) Alberto Mantovani et al. CURRENT OPINION IN IMMUNOLOGY
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of Macrophages
- (2009) David G. DeNardo et al. CANCER CELL
- FRS2 via Fibroblast Growth Factor Receptor 1 Is Required for Platelet-derived Growth Factor Receptor β-mediated Regulation of Vascular Smooth Muscle Marker Gene Expression
- (2009) Pei-Yu Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation
- (2009) S. Kang et al. MOLECULAR AND CELLULAR BIOLOGY
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- The FGF system has a key role in regulating vascular integrity
- (2008) Masahiro Murakami et al. JOURNAL OF CLINICAL INVESTIGATION
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started